文献速递乳腺癌放疗姑息放疗与转移瘤

曲妥珠单抗-美坦新偶联物(T-DM1)联合放疗的安全性特征:系统综述与荟萃分析

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2023-07-10

该系统综述与荟萃分析由欧洲放射肿瘤学会(ESTRO)指南委员会共识推荐项目开展,检索PUBMED/MedLine、Embase和Cochrane数据库,纳入9篇原始研究,汇总T-DM1联合放疗的安全性数据。汇总数据显示3级及以上放射性坏死发生率为17%,而3级及以上放射性肺炎(<1%)和皮肤毒性(1%)发生率很低。结论认为在非转移性乳腺癌局部区域治疗中该联合方案安全性可接受,但颅内照射时需谨慎,并亟需国际共识指南。

要点

  • T-DM1联合放疗的3级及以上放射性坏死汇总发生率为17%。
  • 3级及以上放射性肺炎发生率<1%,3级及以上皮肤毒性发生率为1%。
  • 非转移性乳腺癌局部区域治疗中该组合安全性可接受,颅内照射需谨慎。

核心结论

  • 尽管T-DM1联合术后放疗时肺炎略有增加的担忧,该联合方案在非转移性乳腺癌局部区域治疗中的安全性特征被认为可接受。
  • 颅内部位与T-DM1同步照射时需谨慎。
  • 亟需关于T-DM1联合放疗安全性考虑的国际共识指南。

研究设计与样本

  • 该系统综述与荟萃分析是欧洲放射肿瘤学会(ESTRO)指南委员会关于乳腺癌放疗与靶向治疗整合共识推荐项目的一部分。
  • 检索PUBMED/MedLine、Embase和Cochrane数据库以识别关注T-DM1联合放疗安全性特征的原始研究。
  • 应用纳入标准后,共9篇文章纳入荟萃分析。

主要发现

  • 汇总数据显示3级及以上放射性坏死发生率高,为17%。
  • 3级及以上放射性肺炎发生率<1%,3级及以上皮肤毒性发生率为1%,均很低。

关键数值与推荐

  • 3级及以上放射性坏死汇总发生率为17%。
  • 3级及以上放射性肺炎汇总发生率<1%。
  • 3级及以上皮肤毒性汇总发生率为1%。

临床怎么用

  • 在非转移性乳腺癌局部区域治疗中,T-DM1联合放疗的安全性特征被认为可接受。
  • 颅内部位与T-DM1同步照射时需谨慎。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents. One such agent is trastuzumab emtansine (T-DM1), an antibody drug conjugate that has shown improved outcomes in both early and advanced breast cancer. However, there is currently a lack of comprehensive evidence regarding the safety profile of combining T-DM1 with radiation therapy (RT). In this study, we aim to provide a summary of the available data on the safety of combining RT with T-DM1 in both early and metastatic breast cancer settings. MATERIALS AND METHODS: This systematic review and meta-analysis project is part of the consensus recommendations by the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee on integrating RT with targeted treatments for breast cancer. A thorough literature search was conducted using the PUBMED/MedLine, Embase, and Cochrane databases to identify original studies focusing on the safety profile of combining T-DM1 with RT. RESULTS: After applying eligibility criteria, nine articles were included in the meta-analysis. Pooled data from these studies revealed a high incidence of grade 3 + radionecrosis (17%), while the rates of grade 3 + radiation-related pneumonitis (<1%) and skin toxicity (1%) were found to be very low. CONCLUSION: Although there is some concern regarding a slight increase in pneumonitis when combining T-DM1 with postoperative RT, the safety profile of this combination was deemed acceptable for locoregional treatment in non-metastatic breast cancer. However, caution is advised when irradiating intracranial sites concurrently with T-DM1. There is a pressing need for international consensus guidelines regarding the safety considerations of combining T-DM1 and RT for breast cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Salvestrini V, Kim K, Caini S, et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37437610. doi:10.1016/j.radonc.2023.109805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。